Maven Securities LTD Acquires Shares of 75,000 Immunome, Inc. $IMNM

Maven Securities LTD acquired a new stake in Immunome, Inc. (NASDAQ:IMNM) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $1,611,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after buying an additional 14,398 shares during the period. Creative Planning bought a new stake in Immunome in the second quarter valued at approximately $167,000. Rhumbline Advisers raised its stake in Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after buying an additional 19,526 shares during the period. The Manufacturers Life Insurance Company raised its stake in Immunome by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock valued at $2,612,000 after buying an additional 9,686 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in Immunome in the second quarter valued at approximately $1,021,000. Institutional investors own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Craig Hallum upped their price objective on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Leerink Partners dropped their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Wedbush reiterated an “outperform” rating and set a $31.00 target price on shares of Immunome in a research note on Friday. Barclays assumed coverage on Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Immunome in a research note on Wednesday, May 13th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Insider Transactions at Immunome

In other Immunome news, CFO Max Rosett sold 65,000 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the transaction, the chief financial officer owned 54,037 shares in the company, valued at $1,184,491.04. This trade represents a 54.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director owned 369,347 shares in the company, valued at approximately $7,560,533.09. This trade represents a 9.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 139,438 shares of company stock worth $2,964,664 in the last ninety days. 7.21% of the stock is currently owned by company insiders.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $18.38 on Monday. The firm has a market cap of $2.08 billion, a P/E ratio of -7.72 and a beta of 2.04. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The business’s 50 day moving average is $21.77 and its 200-day moving average is $21.71.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. Analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.